Clinical Trials /

Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC

NCT04028778

Description:

Gefitinib is currently the standard-of-care for patients with activating-EGFR mutant advanced non-small cell lung cancer (NSCLC). However, ~30-40% patients are still nonresponsive, and experience significantly varying duration of response and survival rate. Anlotinib is an efficient multi-target tyrosine kinase inhibitor (TKI) that effectively block the migration and proliferation of endothelial cells and reduce tumor microvascular density by targeting VEGFRs, FGFRs, PDGFRs. It has been proved to be safe and effective in advanced lung cancer after second-line standard chemotherapy failure, which can significantly extend the survival of patients and approves as a third-line treatment for advanced NSCLC. Here, we prepared to evaluate whether the combination of gefitinb and anlotinib can preferably improved survival of untreated NSCLC with EGFR activating mutation.

Related Conditions:
  • Non-Small Cell Lung Carcinoma
Recruiting Status:

Recruiting

Phase:

Phase 3

Trial Eligibility

Document

Title

  • Brief Title: Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC
  • Official Title: A Multicenter, Randomized, Double-Blind Study of Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

Clinical Trial IDs

  • ORG STUDY ID: 2018-FXY-134-内科
  • NCT ID: NCT04028778

Conditions

  • Lung Cancer, Nonsmall Cell

Interventions

DrugSynonymsArms
GefitinibIressaGefitinib + Anlotinib
Anlotinib HydrochlorideGefitinib + Anlotinib

Purpose

Gefitinib is currently the standard-of-care for patients with activating-EGFR mutant advanced non-small cell lung cancer (NSCLC). However, ~30-40% patients are still nonresponsive, and experience significantly varying duration of response and survival rate. Anlotinib is an efficient multi-target tyrosine kinase inhibitor (TKI) that effectively block the migration and proliferation of endothelial cells and reduce tumor microvascular density by targeting VEGFRs, FGFRs, PDGFRs. It has been proved to be safe and effective in advanced lung cancer after second-line standard chemotherapy failure, which can significantly extend the survival of patients and approves as a third-line treatment for advanced NSCLC. Here, we prepared to evaluate whether the combination of gefitinb and anlotinib can preferably improved survival of untreated NSCLC with EGFR activating mutation.

Trial Arms

NameTypeDescriptionInterventions
Gefitinib + AnlotinibExperimentalPatients will be treated with Gefitinib 250mg, p.o., qd and anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; take on an empty stomach (take at the same time every day as possible), every 3 weeks for a cycle.
  • Gefitinib
  • Anlotinib Hydrochloride
Gefitinib + PlaceboPlacebo ComparatorPatients will be treated with Gefitinib 250mg, p.o., qd and placebo to simulate anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; take on an empty stomach (take at the same time every day as possible), every 3 weeks for a cycle
  • Gefitinib

Eligibility Criteria

        Inclusion Criteria:

          -  1.≥ 18 and ≤ 75 years of age

          -  2.Eastern Cooperative Oncology Group(ECOG)performance scale 0 - 1.

          -  3.Life expectancy of more than 3 weeks

          -  4.Histologically confirmed,locally advanced and/or metastatic non-squamous NSCLC of
             stage IIIB (unsuitable for radiotherapy) or IV or recurrent NSCLC with measurable
             lesion/ according to RECIST 1.1 which has not received radiotherapy or cryotherapy.

          -  5.Documented evidence of tumor harboring an activating EGFR mutation (exon19 del and
             L858R)

          -  6.None previous chemotherapy or targeted therapy. NOTE: neoadjuvant and/or adjuvant
             therapy is allowed which is completed before 6 months

          -  7.Prior radiation therapy is allowed if: 25% or less of total bone marrow had been
             irradiated,pelvis and chest had not been irradiated; at least 4 weeks have elapsed
             from the completion of radiation treatment, and the acute toxicity from radiation
             treatment had been recover; irradiated lesion is not including measurable lesions
             unless documented progress after radiation.

          -  8.Adequate hepatic, renal, heart, and hematologic functions (Absolute Neutrophil
             Count(ANC) ≥ 1.5×109/L, Platelet (PLT) ≥ 100×109/L, Hemoglobin(HB) ≥ 100 g/L, total
             bilirubin within 1.5×the upper limit of normal(ULN), and serum transaminase≤2.5×the
             Upper Limit Of Normal(ULN), serum creatine ≤ 1 x Upper Limit Of Normal(ULN),
             creatinine clearance rate ≥ 50ml/min

          -  9.For women of child-bearing age, the pregnancy test results (serum or urine) within 7
             days before enrolment must be negative. They will take appropriate methods for
             contraception during the study until the 8th week post the last administration of
             study drug. For men (previous surgical sterilization accepted), will take appropriate
             methods for contraception during the study until the 8th week post the last
             administration of study drug.

          -  10.Signed and dated informed consent. Willingness and ability to comply with scheduled
             visits, treatment plans, laboratory tests, and other study procedure.

        Exclusion Criteria:

          -  1.small cell lung cancer (including small cell and non-small cell mixed lung cancer)

          -  2.Symptomatic brain metastases (Patients who have no symptoms and is not needed to
             receive therapy before 21 days may participate in this trial, but need to be confirmed
             by MRI\CT or venography that no hematencephalon symptom)

          -  3.Radiologically documented evidence of tumor lesions from large vessels ≤ 5mm or
             major blood vessel invasion or encasement by cancer; Obvious cavity or necrosis formed
             in the tumor.

          -  4. hypertensive patients are in the combination therapy of two or more
             antihypertensive drugs.

          -  5.patients with positive T790M mutation by Gene detection.

          -  6.Patients who suffered from grade II or above myocardial ischemia or myocardial
             infarction, uncontrolled arrhythmias (including QT interval male ≥ 450 ms, female ≥
             470 ms). Grade III-IV cardiac insufficiency according to New York Heart
             Association(NYHA) criteria or echocardiography check: left ventricular ejection
             fraction (LVEF)<50%;

          -  7.History of pulmonary interstitial diseases or concurrent pulmonary interstitial
             diseases.

          -  8.Coagulation disfunction(INR>1.5 or PT>Upper Limit Of Normal(ULN)+4s or Activated
             Partial Thromboplastin Time (APTT) >1.5 Upper Limit Of Normal(ULN)), hemorrhagic
             tendency or receiving the therapy of thrombolysis or anticoagulation

          -  9.Daily hemoptysis up to two teaspoons or more before enrollment

          -  10.History of clinically relevant major bleeding event=<3 months (e.g.
             gastrointestinal hemorrhage, Hemorrhagic acne, bleeding gastric ulcer, occult blood
             test ≥ (++), and vasculitis ;

          -  11.Within 12 months before the first treatment occurs artery / venous thromboembolic
             events, such as cerebral vascular accident (including transient ischemic attack(TIA),
             hematencephalon, cerebral infarction), deep vein thrombosis and pulmonary embolism,
             etc.

          -  12.Known inherited and acquired hemorrhagic and thromboplastic possibility (such as
             hemophilia, coagulopathy, thrombocytopenia, hypersplenism, etc.)

          -  13.Long-term untreated wounds or fractures(in addition to tumor-induced pathological
             fractures)

          -  14.Within 4 weeks of major surgery and/or injures, fractures , ulceration

          -  15.Significant factors that influence the ingestion and absorption of medicine, (e.g.
             unable swallow, chronic diarrhea and intestinal obstruction);

          -  16.History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
             abscess ≤ 6 months.

          -  17.Urine protein≥++, and 24h urine protein quantitation≥1.0g;

          -  18.Symptomatic serous effusion requiring treatment .(including hydrothorax, ascites,
             hydropericardium);

          -  19.Active infection need antimicrobial treatments(such as antibiotics and antiviral
             drugs should be used, excluding anti-hepatitis B treatment and antifungal therapy. )

          -  20.History of psychiatric drugs abuse and not be abstinent, or dysphrenia

          -  21.Less than 4 weeks from the last clinical trial

          -  22.History or concomitant other malignancy except cured basal cell skin cancer, or
             carcinoma in situ of the cervix, or superficial bladder cancer;

          -  23.Administration of strong/potent cytochrome P450 (CYP)3A4 inhibitors within 7 days,
             or inducers within 12 days;

          -  24.Pregnant or breastfeeding women;patients who have fertility are unwilling or unable
             to take effective contraceptive measures;

          -  25.Other conditions regimented at investigators' discretion
      
Maximum Eligible Age:75 Years
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Progress-free survival (PFS)
Time Frame:Approximately 2 Years
Safety Issue:
Description:Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)

Secondary Outcome Measures

Measure:Overall Survival (OS)
Time Frame:Approximately 5 Years
Safety Issue:
Description:OS was defined as the time from the date of randomization to the date of death due to any cause.
Measure:Percentage of Participants With Objective Response (Partial Response [PR] Plus Complete Response [CR]), as Assessed Using RECIST v.1.1
Time Frame:Approximately 2 Years
Safety Issue:
Description:PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions).
Measure:Percentage of Participants With Clinical Benefit, as Assessed According to RECIST v1.1
Time Frame:Approximately 2 Years
Safety Issue:
Description:Clinical benefit was defined as objective response (PR+CR), or no disease progression lasting for more than or equal to (>/=) 24 weeks since randomization. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions). Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression.
Measure:Duration of Objective Response, as Assessed by Investigator Using RECIST v1.1
Time Frame:Approximately 2 Years
Safety Issue:
Description:Duration of objective response: the time from the first tumor assessment that supported the participant's objective response (CR or PR, whichever was first recorded) to first documented disease progression or death due to any cause, whichever occurred first. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Disease progression: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression.

Details

Phase:Phase 3
Primary Purpose:Interventional
Overall Status:Not yet recruiting
Lead Sponsor:Sun Yat-sen University

Last Updated